Drug Profile
Methyl aminolevulinate - Galderma
Alternative Names: 5-ALA methylester; 5-ALA-methylesther; Aminolevulinic acid methyl ester; CD06809-41; Luxerm; MAL-PDT; Methyl 5 aminolevulinate; Methylaminolevulinate; Metvix; Metvix Natural Daylight Photodynamic Therapy - Galderma; Metvix NDL-PDT; Metvix PDT; Metvixia; P 1202; VisonacLatest Information Update: 04 Jan 2024
Price :
$50
*
At a glance
- Originator Norwegian Radium Hospital; PhotoCure
- Developer Galderma; Healthcare Logistics; Photocure
- Class Amino acids; Antineoplastics; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Actinic keratosis; Basal cell cancer; Squamous cell cancer
- Phase II Acne
- Discontinued Skin aging
Most Recent Events
- 04 Jan 2024 No development reported - Phase-III for Actinic keratosis in Puerto Rico (Topical) (Galderma website; January 2024)
- 01 Sep 2021 Galderma terminates a phase III trial for Actinic keratosis in USA and Puerto Rico due to sponsor's decision (Topical) (NCT04269395)
- 04 Mar 2021 Galderma completes a phase III trial in Actinic keratosis in Puerto Rico and USA (Topical) (NCT04085367)